BioNTech (US Operations)

The mRNA cancer vaccine pioneer with $4B revenue and Phase 3 trials underway for personalized cancer immunotherapy, which outperforms #1 Moderna's oncology pipeline in clinical progress. BioNTech's Oxford partnership and pipeline of mRNA cancer vaccines represent a potential paradigm shift in oncology, with 5 candidate vaccines in development targeting 15% of solid tumors.